NasdaqGS:CYTKBiotechs
Cytokinetics Wins Dual MYQORZO Approvals But Faces Execution And Loss Risks
Cytokinetics (NasdaqGS:CYTK) has secured regulatory approval from both the FDA and the European Commission for MYQORZO™, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).
MYQORZO™ is expected to reach patients in the U.S. and Europe with sales commencing in Q1 2026.
The approvals open access to two major markets and introduce a new potential revenue source for Cytokinetics.
Cytokinetics enters this phase with MYQORZO™ approved on both sides of the Atlantic and a current share...